Atazanavir Sulfate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

42 API Suppliers, 25 USDMF, 7 CEP/COS, 15 EU WC, 2 KDMF, 18 NDC API, 21 Listed Suppliers, $ API Reference Price

FINISHED DOSAGE FORMULATIONS

69 FDF Dossiers, 42 FDA Orange Book, 8 Europe, 11 Canada, 2 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 8 DKSH, 4 Faran Shimi Pharmaceutical, 10 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 17 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

46 Fillers, Diluents & Binders, 23 Disintegrants & Superdisintegrants, 22 Direct Compression, 21 Thickeners and Stabilizers, 17 Lubricants & Glidants, 15 Granulation, 13 Coating Systems & Additives, 11 Co-Processed Excipients, 8 Film Formers & Plasticizers, 8 Empty Capsules, 7 Taste Masking, 7 Topical, 7 Emulsifying Agents, 5 Controlled & Modified Release, 4 Parenteral, 4 Solubilizers, 3 Chewable & Orodispersible Aids, 3 Surfactant & Foaming Agents, 3 Coloring Agents, 2 Rheology Modifiers, 1 API Stability Enhancers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 10 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 5 Annual Reports

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 1 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 206353 / DOSAGE - TABLET;ORAL - EQ 300MG BASE;150MG

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
ATAZANAVIR SULFATE(UNII: 4MT4VIE29P) (ATAZANAVIR - UNII:QZU4H47A3S)	ATAZANAVIR	300mg
COBICISTAT(UNII: LW2E03M5PG) (COBICISTAT - UNII:LW2E03M5PG)	COBICISTAT	150mg

Inactive Ingredients

Ingredient Name	A-S Medication Solutions
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
CROSCARMELLOSE SODIUM(M28OL1HH48)
CROSPOVIDONE (15 MPA.S AT 5%)(68401960MK)
CROSPOVIDONE(68401960MK)
HYDROXYPROPYL CELLULOSE (1200000 MW)(RFW2ET671P)
HYDROXYPROPYL CELLULOSE (TYPE H)(RFW2ET671P)
MAGNESIUM STEARATE(70097M6I30)
MICROCRYSTALLINE CELLULOSE(OP1R32D61U)
SILICON DIOXIDE(ETJ7Z6XBU4)
SODIUM STARCH GLYCOLATE TYPE A POTATO(5856J3G2A2)
STEARIC ACID(4ELV7Z65AP)

Drug Product Composition: Atazanavir Sulfate